Trial Profile

A First-In-Human trial evaluating bimatoprost using the SpyGlass platform in patients with glaucoma or ocular hypertension

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimatoprost (Primary)
Indications Glaucoma; Ocular hypertension
Focus Adverse reactions; First in man

Most Recent Events

24 Apr 2025 According to a SpyGlass Pharma media release, data from this study will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, the company look forward to providing further data updates from this ongoing study
24 Apr 2025 18 month data presented in the SpyGlass Pharma Media Release
17 Oct 2024 According to a SpyGlass Pharma media release, data from this study were presented during the Eyecelerator Ophthalmic Innovation Conference prior to the American Academy of Ophthalmology annual meeting in Chicago, Ill.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com